Clinical outcomes of conjugated linoleic acid supplementation in the overweight and the obese: a study protocol

Authors

  • Klaudia Łochocka Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
  • Aleksandra Glapa Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
  • Jan Krzysztof Nowak Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
  • Monika Duś-Żuchowska Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
  • Katarzyna Grabańska Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poland
  • Paweł Bogdański Department of Internal Medicine, Metabolic Disorders and Hypertension, Poznan University of Medical Sciences, Poland
  • Ewa Fidler Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
  • Edyta Mądry Department of Physiology, Poznan University of Medical Sciences, Poland
  • Jarosław Walkowiak Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland

DOI:

https://doi.org/10.20883/medical.e86

Keywords:

obesity, randomized, digestion, absorption, body composition, lipid profile, endothelial dysfunction, mineral status, breath test, 13C, adipokines

Abstract

This is the protocol of a study aiming to assess the impact of conjugated linoleic acid (CLA) on anthropometric parameters, body composition and densitometric parameters, carbohydrate and fat digestion and absorption, total energy expenditure, glucose and insulin homeostasis, lipid profile, adipokines concentrations, polyunsaturated fatty acids levels, markers of endothelial dysfunction and mineral status in humans. Seventy-four adult volunteers (BMI ≥ 25 kg/m2) will be randomized to receive 3.0 g of 80% CLA (50:50 cis-9, trans-11 and trans-10, cis-12 isomers) or 3.0 g of linoleic acid daily for 3 months. A range of parameters will be measured at baseline and after the intervention.

Downloads

Download data is not yet available.

References

Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014; 384(9945):766–781.

Kennedy A, Martinez K, Schmidt S, Mandrup S, LaPoint K, McIntosh M. Antiobesity mechanisms of action of conjugated linoleic acid. J Nutr Biochem. 2010;21(3): 171–179.

Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000;130(12):2943–2948.

Riserus U, Arner P, Brismar K, Vessby B. Treatment With Dietary trans10cis12 Conjugated Linoleic Acid Causes Isomer-Specific Insulin Resistance in Obese Men With the Metabolic Syndrome. Diabetes Care. 2002;25(9): 1516–1521.

Joseph SV, Jacques H, Plourde M, Mitchell PL, McLeod RS, Jones PJH. Conjugated Linoleic Acid Supplementation for 8 Weeks Does Not Affect Body Composition, Lipid Profile, or Safety Biomarkers in Overweight, Hyperlipidemic Men. J Nutr. 2011;141(7):1286–1291.

Gaullier J-M, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135(4):778–784.

Pfeuffer M, Fielitz K, Laue C, Winkler P, Rubin D, Helwig U, et al. CLA does not impair endothelial function and decreases body weight as compared with safflower oil in overweight and obese male subjects. J Am Coll Nutr. 2011;30(1):19–28.

Chen S-C, Lin Y-H, Huang H-P, Hsu W-L, Houng J-Y, Huang C-K. Effect of conjugated linoleic acid supplementation on weight loss and body fat composition in a Chinese population. Nutrition. 2012;28(5):559–565.

Rodrigues R, Soares J, Garcia H, Nascimento C, Medeiros M, Bomfim M, et al. Goat milk fat naturally enriched with conjugated linoleic acid increased lipoproteins and reduced triacylglycerol in rats. Mol Basel Switz. 2014;19(3):3820–3831.

Chinnadurai K, Kanwal H, Tyagi A, Stanton C, Ross P. High conjugated linoleic acid enriched ghee (clarified butter) increases the antioxidant and antiatherogenic potency in female Wistar rats. Lipids Health Dis. 2013;12(1):121.

Risérus U, Vessby B, Arnlöv J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J Clin Nutr. 2004;80(2): 279–283.

Kim J, Paik H-D, Shin M-J, Park E. Eight weeks of conjugated linoleic acid supplementation has no effect on antioxidant status in healthy overweight/obese Korean individuals. Eur J Nutr. 2012;51(2):135–141.

Xu X, Storkson J, Kim S, Sugimoto K, Park Y, Pariza MW. Short-term intake of conjugated linoleic acid inhibits lipoprotein lipase and glucose metabolism but does not enhance lipolysis in mouse adipose tissue. J Nutr. 2003;133(3):663–667.

Ramos R, Mascarenhas J, Duarte P, Vicente C, Casteleiro C. Conjugated linoleic acid-induced toxic hepatitis: first case report. Dig Dis Sci. 2009;54(5):1141–1143.

Nortadas R, Barata J. Fulminant hepatitis during self-medication with conjugated linoleic acid. Ann Hepatol. 2012;11(2):265–267.

Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85(5):1203–1211.

Downloads

Published

2014-12-31

Issue

Section

Case Study

How to Cite

1.
Łochocka K, Glapa A, Nowak JK, Duś-Żuchowska M, Grabańska K, Bogdański P, et al. Clinical outcomes of conjugated linoleic acid supplementation in the overweight and the obese: a study protocol. JMS [Internet]. 2014 Dec. 31 [cited 2024 Nov. 22];83(4):318-21. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/86